Table 1 Baseline Clinical and CPET Characteristics by HFpEF Status in the MGH CPET Sample

From: Eicosanoid and eicosanoid-related inflammatory mediators and exercise intolerance in heart failure with preserved ejection fraction

 

No HFpEF

HFpEF

p-value

N

N = 253

N = 257

 

Clinical characteristics

Age, years

50 (16)

61 (13)

8.21 E−15

Women, n (%)

166 (66%)

154 (60%)

0.22

White race, n (%)

240 (95%)

246 (96%)

0.22

BMI, kg/m2

27.4 (5.9)

31.0 (6.6)

9.33 E−11

Obesity, n (%)

76 (30%)

137 (53%)

5.77 E−08

Hypertension, n (%)

101 (40%)

164 (64%)

1.09 E−07

Myocardial infarction, n (%)

7 (3%)

11 (4%)

0.49

Diabetes mellitus, n (%)

24 (10%)

58 (23%)

9.59 E−05

Atrial fibrillation, n (%)

16 (6%)

52 (20%)

7.13 E−06

Left atrial enlargement, n (%)

38 (20%)

88 (41%)

9.37 E−06

Left ventricular hypertrophy, n (%)

22 (11%)

62 (29%)

2.94 E−05

COPD, n (%)

14 (5%)

30 (12%)

0.02

ILD, n (%)

14 (5%)

16 (6%)

0.89

OSA, n (%)

41 (16%)

67 (26%)

0.009

Past or current smoking, n (%)

78 (31%)

123 (48%)

0.00012

Current smoking, n (%)

10 (4%)

7 (3%)

0.60

Diuretic use, n (%)

34 (13%)

106 (41%)

4.03 E−12

Aspirin use, n (%)

70 (28%)

109 (43%)

0.001

Statin use, n (%)

56 (22%)

123 (48%)

1.59 E−09

Creatinine (mg/dL)

0.92 (0.23)

1.08 (0.86)

0.01

Estimated GFR, mL/min/1.73m2

83 (20)

72 (22)

1.20 E−07

NT-pro BNP, pg/mL

43.0 (23.5–104.4)

105.8 (51.2–302.7)

1.69 E−14

hsCRP, mg/L

1.16 (0.52–3.17)

2.84 (1.24–5.98)

6.46 E−12

LV ejection fraction, %

65 (6)

65 (8)

0.72

CPET characteristics

Peak VO2, mL/kg/min

19.7 (6.1)

14.7 (3.9)

2.22 E−16

Predicted VO2, %

80 (18)

73 (15)

2.37 E−06

Peak RER

1.18 (0.11)

1.15 (0.11)

0.006

VE/VCO2 slope

32.1 (5.7)

34.1 (6.4)

0.0002

C(a-v)O2, mL/100 mL

11.0 (2.0)

11.5 (2.2)

0.009

ΔSBP, mmHg

49 (30)

51 (37)

0.44

ΔPCWP/ΔCO, mmHg/L/min

1.23 (0.54)

3.39 (2.55)

0.001

ΔPAP/ΔCO, mmHg/L/min

2.15 (1.98)

4.15 (2.91)

2.20 E−16

Predicted heart rate, %

88 (11)

81 (15)

<0.001

  1. Values are means (standard deviations) or median (inter-quartile range) unless otherwise noted. p < 0.05 considered significant by t-test, chi-squared test, or Kruskal-Wallis (for NT-pro BNP and hsCRP).
  2. BMI body mass index, CO cardiac output, COPD chronic obstructive pulmonary disease, GFR glomerular filtration rate, hsCRP high sensitivity C-reactive protein, ILD interstitial lung disease, LV left ventricular, NT-pro BNP N-terminal pro B-type natriuretic peptide, OSA obstructive sleep apnea, PAP pulmonary artery pressure, PCWP pulmonary capillary wedge pressure, RER respiratory exchange ratio, SBP systolic blood pressure.
Back to article page